The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) positive cancers account for 15–20% of all breast tumors. Several drugs have been approved in the metastatic setting, including monoclonal antibodies, tyrosine kinase inhibitors (TKI) and, more recently, antibody-drug conjugates. Neratinib is a pan-HER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Chilà, Giovanna, Guarini, Vincenzo, Galizia, Danilo, Geuna, Elena, Montemurro, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8232377/
https://ncbi.nlm.nih.gov/pubmed/34188449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S281599
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados